At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 70 enrolled
Drug / intervention
Liraglutide Pen Injector [Saxenda] +1 moredrug
Likely dose
Liraglutide Pen Injector [Saxenda] 3.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery
In Brief
A Phase 4 clinical trial evaluating Liraglutide Pen Injector [Saxenda] and Placebo for Obesity. Completed, enrolled 70 participants across 1 site.
Detailed Summary
A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartAug 2018
Primary CompletionNov 2019
Study CompletionJun 2020
TodayJul 2026
First PostedNov 14, 2017
Enrollment StartAug 22, 2018
Primary CompletionNov 28, 2019
Study CompletionJun 11, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.6 years ago
Interventions
Liraglutide Pen Injector [Saxenda]drug
Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.
Placebodrug
Daily subcutaneous injection